Agenus (AGEN) is a pharmaceutical company that has long studied the immune system and worked to create therapies for infectious diseases and cancers. Its QS-21 Stimulon is one of the ingredients in GSK's Shingrix vaccine, which has been a big success. The main future value of Agenus, however, lies in its pipeline of cancer immunotherapies. Agenus could apply to the FDA later this year for potential commercial approval of two of those, balstilimab and zalifrelimab.
To understand the potential value of these new therapies, it is important to see where they fit in